News

Article

Clinicians Report Unmet Needs Regarding Training Fellows for Community-Based Careers

Author(s):

Clinicians say that there are substantial unmet needs in terms of deliberately training hematology/oncology fellows for community-based careers.

Substantial unmet needs are present in the training of hematology and oncology fellows for community-based careers in terms of providing community-based longitudinal clinical experiences and curricula discussing aspects of health care delivery, according to findings from a national survey of clinicians in community or academic-community hybrid settings in the United States.

Survey results which were published in JCO Oncology Practice, showed that 41.6% (binomial 95% CI, 32.8%-50.7%) of oncologists and hematologists (n = 125) from 25 states reported receiving training in a community-based setting. Physicians noted that valuable experiences during training could have included rotations in community settings (47%), direct mentorship from community-based physicians (40%), and longitudinal clinic in a community setting (36%). However, most respondents (64.8%) reported they were very satisfied during training for current professional responsibilities and almost all (98%) were satisfied with their training during fellowship. It was more likely that respondents who were in practice for less than 10 years received training specific to a community-based career (RR, 2.13; 95% CI, 1.18-3.86).

Oncologists and hematologists also listed medical operations and administration (63%), health policy (35%), and quality improvement (27%) as curricula of interest during training.

“Trends noted in surveys conducted by various national organizations indicate that 38%-56% of trainees enter nonacademic clinical settings after fellowship training. In our survey, respondents indicated factors related to geography, work-life balance, patient care–focused careers, and compensation to be key factors in their decision to pursue careers in community-based and academic-hybrid settings,” study authors wrote.

The cross-sectional online survey was conducted from March 2022 to February 2023 and featured 14 multiple choice questions across 3 main domains. The domains encompassed current practice setting and satisfaction, opportunities for community-based training during fellowship, and further clinical or didactic experiences that were desired during fellowship to better prepare respondents for community-based careers.

In addition to demographic questions that included sex, years in clinical practice, and location of fellowship training, practicing hematologists and oncologists were asked 2 open-ended questions. “What would better equip a hematologist/oncologist in training to work effectively in your current clinical practice setting?” the first question asked. The second question asked, “what comments or suggestions do you have regarding a professional development pathway for hematology/oncology trainees with a planned focus in community-based hematology/oncology?”

When compiling responses from the open-ended questions, investigators captured themes regarding optimizing clinical training during fellowship for community-based careers showing that respondents thought that mentoring with community providers, exposure to various cases, and health policy/diversity and inclusion/community outreach among others would be helpful. Clinicians also cited finances/billing, patient advocacy, provider wellness/work life balance, health care delivery, clinical research in the community setting, and supportive oncology and community training as important areas of nonclinical training during fellowship for community-based careers. Finally, respondents cited barriers to specific training in the hematology/oncology fellowship for those perusing community-based carriers such as stigma and an imbalance in training.

Varying views were also reported in terms of a need for a community-focused fellowship track with 1 clinician responding it would be a good idea, however the view that academic positions are more prestigious than community ones may lead to bias against fellows looking to pursue a community practice role. Another respondent noted that patient care professional development is almost the same for community and academic oncologists.

Most clinicians surveyed were male (63.2%), White (57.6%), and were certified in both oncology and hematology (64%). Clinicians were in practice for more than 20 years (35.2%), 10 to 20 years (32.8%), or had graduated in the past 5 years (16%). Respondents were based in academically affiliated community centers (32.8%), community practices that are part of large cancer networks but do not have a formal academic affiliation (26.4%), and academic centers (14%). When clinicians were asked why they chose a community-based setting, work-life balance (59%), the desire to have a primarily clinically focused career (47%), financial compensation (39.2%), and previous experiences with mentors in community-based careers (20%) were reasons cited. Further, 92% of clinicians said that they were satisfied with their career choice.

“Our findings provide a foundation on which to prospectively design clinical experiences and targeted curricula in a goal- concordant manner for hematology/oncology fellows who plan to pursue careers in community-based settings,” study authors wrote in conclusion.

Reference

Agrawal S, Patell R, Dodge LE, et al. Defining the educational needs for a community-based hematology/oncology career: a national needs assessment. JCO Oncol Pract. Published online February 8, 2024. doi:10.1200/OP.23.00698

Related Videos
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.
Minoo Battiwalla, MD, MS